Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Cannabinoid regulation of angiotensin II-induced calcium signaling in striatal neurons

  • Rivas Santisteban, Rafael|||0000-0002-2078-6819
  • Muñoz, Ana
  • Lillo, Jaume
  • Raïch, Iu|||0000-0001-6271-0495
  • Rodríguez Pérez, Ana Isabel|||0000-0003-1354-8799
  • Navarro Brugal, Gemma|||0000-0003-4654-0873
  • Labandeira-García, José Luis|||0000-0002-8243-9791
  • Franco, Rafael|||0000-0003-2549-4919
Calcium ion (Ca 2+) homeostasis is crucial for neuron function and neurotransmission. This study focused on the actions mediated by the CB receptor (CBR), the most abundant G protein-coupled receptor (GPCR) in central nervous system (CNS) neurons, over by the ATR, which is one of the few G protein-coupled CNS receptors able to regulate cytoplasmic Ca 2+ levels. A functional interaction suggesting a direct association between these receptors was detected. AT-CB receptor heteromers (ATCBHets) were identified in HEK-293T cells by bioluminescence resonance energy transfer (BRET 2). Functional interactions within the AT-CB complex and their potential relevance in Parkinson's disease (PD) were assessed. In situ proximity ligation assays (PLA) identified ATCBHets in neurons, in which an important finding was that Ca 2+ level increase upon ATR activation was reduced in the presence of cannabinoids acting on CBRs. ATCBHet expression was quantified in samples from the 6-hydroxydopamine (6-OHDA) hemilesioned rat model of PD in which a lower expression of ATCBHets was observed in striatal neurons from lesioned animals (versus non-lesioned). ATCBHet expression changed depending on both the lesion and the consequences of levodopa administration, i.e., dyskinesias versus lack of involuntary movements. A partial recovery in ATCBHet expression was detected in lesioned animals that developed levodopa-induced dyskinesias. These findings support the existence of a compensatory mechanism mediated by ATCBHets that modulates susceptibility to levodopa-induced dyskinesias in PD. Therefore, cannabinoids may be useful in reducing calcium dyshomeostasis in dyskinesia.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Allosterism in the adenosine A2A and cannabinoid CB2 heteromer

  • Llinas del Torrent, Claudia|||0000-0002-6772-6856
  • Raïch, Iu|||0000-0001-6271-0495
  • Gonzalez, Angel|||0000-0002-2284-8307
  • Lillo Jové, Jaume|||0000-0001-7712-0850
  • Casajuana-Martin, Nil|||0000-0002-9007-274X
  • Franco, Rafael|||0000-0003-2549-4919
  • Pardo Carrasco, Leonardo|||0000-0003-1778-7420
  • Navarro Brugal, Gemma|||0000-0003-4654-0873
Background and Purpose: Allosterism is a regulatory mechanism for GPCRs that can be attained by ligand-binding or protein-protein interactions with another GPCR. We have studied the influence of the dimer interface on the allosteric properties of the A2A receptor and CB2 receptor heteromer. Experimental Approach: We have evaluated cAMP production, phosphorylation of signal-regulated kinases (pERK1/2), label-free dynamic mass redistribution, β-arrestin 2 recruitment and bimolecular fluorescence complementation assays in the absence and presence of synthetic peptides that disrupt the formation of the heteromer. Molecular dynamic simulations provided converging evidence that the heteromeric interface influences the allosteric properties of the A2AR-CB2R heteromer. Key Results: Apo A2AR blocks agonist-induced signalling of CB2R. The disruptive peptides, with the amino acid sequence of transmembrane (TM) 6 of A2AR or CB2R, facilitate CB2R activation, suggesting that A2AR allosterically prevents the outward movement of TM 6 of CB2R for G protein binding. Significantly, binding of the selective antagonist SCH 58261 to A2AR also facilitated agonist-induced activation of CB2R. Conclusions and Implications: It is proposed that the A2AR-CB2R heteromer contains distinct dimerization interfaces that govern its functional properties. The molecular interface between protomers of the A2AR-CB2R heteromer interconverted from TM 6 for apo or agonist-bound A2AR, blocking CB2R activation, to mainly the TM 1/7 interface for antagonist-bound A2AR, facilitating the independent opening of intracellular cavities for G protein binding. These novel results shed light on a different type of allosteric mechanism and extend the repertoire of GPCR heteromer signalling.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The Leu/Val6.51 Side Chain of Cannabinoid Receptors Regulates the Binding Mode of the Alkyl Chain of Δ9-Tetrahydrocannabinol

  • Llinas del Torrent, Claudia|||0000-0002-6772-6856
  • Raïch, Iu|||0000-0001-6271-0495
  • Gonzalez, Angel|||0000-0002-2284-8307
  • Casajuana-Martin, Nil|||0000-0002-9007-274X
  • Lillo, Jaume
  • Rebassa, Joan Biel
  • Ferreiro-Vera, Carlos
  • Sánchez de Medina, Verónica
  • Franco, Rafael|||0000-0003-2549-4919
  • Navarro Brugal, Gemma|||0000-0003-4654-0873
  • Pardo Carrasco, Leonardo|||0000-0003-1778-7420
(-)-Δ-trans-tetrahydrocannabinol (THC), which is the principal psychoactive constituent of Cannabis, mediates its action by binding to two members of the G-protein-coupled receptor (GPCR) family: the cannabinoid CB (CBR) and CB (CBR) receptors. Molecular dynamics simulations showed that the pentyl chain of THC could adopts an I-shape conformation, filling an intracellular cavity between Phe and Trp for initial agonist-induced receptor activation, in CBR but not in CBR. This cavity opens to the five-carbon chain of THC by the conformational change of the γ-branched, flexible, Leu side chain of CBR, which is not feasible by the β-branched, mode rigid, Val side chain of CBR. In agreement with our computational results, THC could not decrease the forskolin-induced cAMP levels in cells expressing mutant CBR receptor but could activate the mutant CBR receptor as efficiently as wild-type CBR. Additionally, JWH-133, a full CBR agonist, contains a branched dimethyl moiety in the ligand chain that bridges Phe and Val for receptor activation. In this case, the substitution of Val to Leu in CBR makes JWH-133 unable to activate CBR. In conclusion, our combined computational and experimental results have shown that the amino acid at position 6.51 is a key additional player in the initial mechanism of activation of GPCRs that recognize signaling molecules derived from lipid species.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Design of Small Non-Peptidic Ligands That Alter Heteromerization between Cannabinoid CB and Serotonin 5HT Receptors

  • Matsoukas, Minos-Timotheos|||0000-0002-4642-8163
  • Ciruela-Jardí, Marc|||0009-0001-9920-8789
  • Gallo, Maria|||0000-0001-9099-7235
  • Ferré, Sergi|||0000-0002-1747-1779
  • Andreu Martínez, David|||0000-0002-6317-6666
  • Casadó, Vicent|||0000-0002-1764-3825
  • Pardo Carrasco, Leonardo|||0000-0003-1778-7420
  • Moreno, Estefanía|||0000-0002-2491-5753
Activation of cannabinoid CB receptors (CBR) by agonists induces analgesia but also induces cognitive impairment through the heteromer formed between CBR and the serotonin 5HT receptor (5HTR). This side effect poses a serious drawback in the therapeutic use of cannabis for pain alleviation. Peptides designed from the transmembrane helices of CBR, which are predicted to bind 5HTR and alter the stability of the CBR-5HTR heteromer, have been shown to avert CBR agonist-induced cognitive impairment while preserving analgesia. Using these peptides as templates, we have now designed nonpeptidic small molecules that prevent CBR-5HTR heteromerization in bimolecular fluorescence complementation assays and the heteromerization-dependent allosteric modulations in cell signaling experiments. These results provide proof-of-principle for the design of optimized ligand-based disruptors of the CBR-5HTR heteromer, opening new perspectives for in vivo studies.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The NADPH Link between the Renin Angiotensin System and the Antioxidant Mechanisms in Dopaminergic Neurons

  • Franco, Rafael|||0000-0003-2549-4919
  • Serrano-Marín, Joan|||0000-0001-9316-0721
  • Navarro Brugal, Gemma|||0000-0003-4654-0873
  • Rivas Santisteban, Rafael|||0000-0002-2078-6819
The renin angiotensin system (RAS) has several components including signaling peptides, enzymes, and membrane receptors. The effort in characterizing this system in the periphery has led to the approval of a class of antihypertensives. Much less is known about RAS in the central nervous system. The production of RAS peptides and the expression of several RAS enzymes and receptors in dopaminergic neurons of the substantia nigra has raised expectations in the therapy of Parkinson's disease, a neurodegenerative condition characterized by lack of dopamine in the striatum, the motor control region of the mammalian brain. On the one hand, dopamine production requires reducing power. On the other hand, reducing power is required by mechanisms involved in REDOX homeostasis. This review focuses on the potential role of RAS in the regulation of neuronal/glial expression of glucose-6-phosphate dehydrogenase, which produces the NADPH required for dopamine synthesis and for reactive oxygen species (ROS) detoxification. It is known that transgenic expression of the gene coding for glucose-6-phosphate dehydrogenase prevents the death of dopaminergic nigral neurons. Signaling via angiotensin II G protein-coupled receptors, AT or AT, leads to the activation of protein kinase A and/or protein kinase C that in turn can regulate glucose-6- phosphate dehydrogenase activity, by Ser/Thr phosphorylation/dephosphorylation events. Long-term effects of AT or AT receptor activation may also impact on the concentration of the enzyme via activation of transcription factors that participate in the regulation of gene expression in neurons (or glia). Future research is needed to determine how the system can be pharmacologically manipulated to increase the availability of NADPH to neurons degenerating in Parkinson's disease and to neuroprotective glia.